Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis

Few therapy options exist for patients with advanced papillary and anaplastic thyroid cancer. We and others have previously identified c-Src as a key mediator of thyroid cancer pro-tumorigenic processes and a promising therapeutic target for thyroid cancer. To increase the efficacy of targeting Src...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessler, Brittelle E., Mishall, Katie M., Kellett, Meghan D., Clark, Erin G., Pugazhenthi, Umarani, Pozdeyev, Nikita, Kim, Jihye, Tan, Aik Choon, Schweppe, Rebecca E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450711/
https://www.ncbi.nlm.nih.gov/pubmed/30531837
http://dx.doi.org/10.1038/s41388-018-0617-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450711/
https://www.ncbi.nlm.nih.gov/pubmed/30531837
http://dx.doi.org/10.1038/s41388-018-0617-1

Ejemplares similares